why choose us

First received: October 09, 2023

Clinical Trial: Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Solid Tumors

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Study to Evaluate the Safety and Tolerability of GS-9911 as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors

Brief Summary: The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-9911 when given alone or in combination with an anti-programmed cell death protein 1 (PD-1) monoclonal antibody in participants with advanced solid tumors.The primary objectives of this study are to:Assess the safety and tolerability of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumorsIdentify the maximum tolerated dose (MTD)/maximum…

Read more